Trial
NCT03132324
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
Sickle Cell Disease
Intervention
INCB059872
Why stopped
This study is terminated due to a business decision not to pursue INCB059782 in Sickle Cell Disease indication.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-28